ORIENTBIO Inc.
Financials
Valuation Metrics
ORIENTBIO Inc.'s Market Cap is ₩541B. At end of 2025 it was ₩713B. Ranked #1724 of 2,421 in KR market (top 71%), #679 of 781 on KOSPI (top 87%), #183 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 79%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 54.13B KRW | KR#1,724/2,421 Sec#183/231 |
| Revenue | 29.75B KRW | KR#2,034/2,421 Sec#140/231 |
| Net Income | -4.57B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 81.62B KRW | KR#1,927/2,421 Sec#159/231 |
| Net Assets | 68.54B KRW | KR#1,698/2,421 Sec#145/231 |
| Employees | 106 | KR#1,602/2,421 Sec#125/231 |
| Value | ||
| P/B | 0.79x | KR#1,251/2,421 Sec#75/231 |
| P/S | 1.82x | KR#1,750/2,421 Sec#100/231 |
| FCF Yield | 1.01% | KR#1,134/2,421 Sec#82/231 |
| Profitability | ||
| ROE | -6.66% | KR#1,852/2,421 Sec#133/231 |
| ROA | -5.60% | KR#1,960/2,421 Sec#143/231 |
| Op. Margin | -13.89% | KR#2,054/2,421 Sec#139/231 |
| Revenue Growth | 1.21% | KR#1,443/2,421 Sec#143/231 |
| Financial Health | ||
| Debt Ratio | 19.07% | KR#345/2,421 Sec#46/231 |
| FCF | 547.9M KRW | KR#1,178/2,421 Sec#89/231 |
| Cash | 5.83B KRW | KR#1,952/2,421 Sec#176/231 |
| Current Ratio | 7.82x | KR#149/2,421 Sec#31/231 |
| Performance | ||
| 1Y Return | -20.61% | KR—/2,421 Sec—/231 |
| 1M Return | 5.43% | KR—/2,421 Sec—/231 |
| From 52W High | -44.06% | KR#1,112/2,421 Sec#84/231 |
| 1Y MDD | -44.47% | KR#748/2,421 Sec#57/231 |
| Trading | ||
| Volume | 756,545 shares | KR—/2,421 Sec—/231 |
| Trading Value | 671.7M KRW | KR—/2,421 Sec—/231 |
| Foreign Own. | 0.42% | KR#2,233/2,421 Sec#214/231 |
| Per Share | ||
| EPS | -77 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,156 KRW | KR#2,271/2,421 Sec#204/231 |
Company Info
Established in 1959, the company merged with Biogenomics in 2003 and spun off its watch business in 2005. It operates in laboratory animal production and life science research and development, holding a technical alliance with Charles River Laboratories. The company produces high-quality biological resources using Korea's largest land area and breeding facilities, and also runs a laboratory equipment CRO business. It is dedicated to enhancing technological competitiveness through bio-industry facility construction, advanced equipment development, and clinical trials for new hair loss drugs. Orient Bio is headquartered in Seongnam-si, Gyeonggi.